FDA Approves Single-Tablet Combination of Macitentan and Tadalafil for Pulmonary Arterial Hypertension

In clinical trials, the newly approved Opsynvi led to a greater drop in pulmonary vascular resistance after 16 weeks compared with both tadalafil and macitentan monotherapy.

Source link
#FDA #Approves #SingleTablet #Combination #Macitentan #Tadalafil #Pulmonary #Arterial #Hypertension